Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data covering 2020 and 2021GlobeNewsWire • 08/29/22
Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®GlobeNewsWire • 08/25/22
Alvotech to Participate in Two Upcoming Investor Conferences in September 2022GlobeNewsWire • 08/24/22
Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022GlobeNewsWire • 08/15/22
Alvotech's Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in IcelandGlobeNewsWire • 08/12/22
Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company's Proposed Generic to Xifaxan® for IBS-DBusiness Wire • 08/11/22
Bears are Losing Control Over Alvotech (ALVO), Here's Why It's a 'Buy' NowZacks Investment Research • 08/05/22
Wall Street Analysts Think Alvotech (ALVO) Could Surge 119%: Read This Before Placing a BetZacks Investment Research • 08/05/22
Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®GlobeNewsWire • 07/20/22
Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded CompanyGlobeNewsWire • 07/14/22
Increase of share capital and creation of treasury share pool to meet obligations with respect to Warrants issued by Alvotech, the Management Incentive Plan, as well as option to issue shares pursuant to the SEPA facility with YorkvilleGlobeNewsWire • 07/05/22
Alvotech Debuts on NASDAQ First North Growth Market Becoming First Dual-Listed Icelandic Company in United States and IcelandGlobeNewsWire • 06/22/22
Publication of a Company Description and Intended Listing on First North IcelandGlobeNewsWire • 06/21/22
Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16Business Wire • 06/15/22